FDA’s CAR-T safety probe; AbbVie’s $10B ADC wager; Pfizer’s GLP-1 setback; Acelyrin’s CRO drama; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We’re of­fi­cial­ly in the fi­nal month of the year, and this week, some of the year’s biggest trends are fea­tur­ing in the top head­lines, from GLP-1s to AD­Cs. As you be­gin plan­ning for 2024, do check out our live and vir­tu­al pro­gram­ming at the JP Mor­gan con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.